Abstract
In the present day scenario, even if many advances in diabetic therapy have been sought, but it is still in its formative years. Nanotechnology has brought a range of novel promises into biological discovery and medical practice. Nanoparticulate drug delivers have revolutionized drug delivery, allowing therapeutic agents to be selectively targeted for organs, tissues and cell specific levels, minimizing exposure of healthy tissues to drugs. Keeping all the views in mind, Glimepiride loaded PLGA nanoparticles (NPs) were prepared by the solvent evaporation method. Physicochemical characterization of NPs included dynamic laser spectroscopy and atomic force microscopy confirmed the mean particle diameter of NPs was ~300 nm with spherical morphology. Fourier transform infrared spectroscopy and differential scanning calorimetry analysis depicted no interaction between the drug and polymer in formulation. Drug encapsulation efficiency was found to be ~55 % and it released from NPs in a sustained manner. Blood glucose level of glimepiride loaded NPs treated to diabetic rats was reduced significantly to normal level compared with native drug treated group. Thus, this system could facilitate to achieve a sustained formulation resulting in reduced dose frequency and improved patient compliance for type-2 diabetes mellitus management.
Keywords: Diabetes, drug delivery, Glimepiride, Nanoparticles, PLGA nanoparticles, Release kinetics.
Graphical Abstract